Cell Therapy Catapult Signs Agreement with Kanagawa Prefecture, Japan
News Nov 30, 2015
The agreement was signed between Kuroiwa Yuji, Governor of the Kanagawa Prefecture, and Keith Thompson, the CEO of the Cell Therapy Catapult.
The agreement involves a commitment for cooperation in the promotion of the practical application and commercialisation of regenerative medicine and cell therapy in both Japan and the UK. The Cell Therapy Catapult, by co-operating with industry, academic institutions and the new Life Innovation Centre in Kanagawa Prefecture, is expected to provide partnerships that will enable both Japanese and British firms to internationalise the development of these advanced therapies. The Kanagawa Prefecture has the second largest population after Tokyo and contains considerable innovation in cell therapy and regenerative medicine. The Life Innovation Centre is strategically located next to Tokyo’s Haneda International Airport providing for ease of logistics in shipping cell therapies between Tokyo, Japan and Cell Therapy Catapult facilities near Heathrow, London, UK.
“This memorandum of understanding is the first agreement between the Cell Therapy Catapult and Japan. This will enable us to develop strong linkages that should help UK firms work in Japan through the Kanagawa Prefecture and for Japanese firms and institutions to develop linkages in the UK and Europe,” said Keith Thompson, CEO of the Cell Therapy Catapult. “In addition, the challenges of an aging population are felt most acutely in Japan. Innovative cell and gene therapies under development in the UK and Japan will play a role in enabling longer, healthier and active lives. We hope that the memorandum of understanding will be a fresh initiative to increase collaboration, mutual understanding and friendship between the UK and the Kanagawa Prefecture.”
“In the Kanagawa Prefecture, we are already promoting a variety of initiatives towards the promotion of regenerative medicine and the cell therapy field. In order to develop this further, we are collaborating with the Cell Therapy Catapult, as it is already at an advanced stage of promoting leading initiatives in this field in the UK,” Kuroiwa Yuji, governor of the Kanagawa Prefecture. “It is the first time that the Cell Therapy Catapult has entered into the memorandum of understanding with an administrative institution in Japan. The promotion of Japanese/UK collaboration regarding the regenerative medicine and cell therapy industries is a high priority in Japan. We have a great expectation that the signing of this ⅯoU will achieve the acceleration of the industrialisation of this sector in the future.”
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Studying Ebola-Host Cell Interaction Helps Find Targets for Antiviral DrugsNews
In some ways, the Ebola virus operates like a vampire; only after it is politely invited in to a host cell does it take up the task of destroying everything in its path. In a new study researchers seek to elucidate quantitatively the biomechanical mechanism of Ebola-host cell interaction, providing potential new targets for antiviral drug development.READ MORE